

03C0



Electronic Filing System (EFS) Data
Electronic Patent Application Submission
USPTO Use Only

EFS ID: 40253
Application ID: 09994466
Title of Invention: THERAPEUTIC BINDING AGENTS
AGAINST MUC-1 ANTIGEN AND
METHODS FOR THEIR USE
First Named Inventor: Ragupathy Madiyaladan
Domestic/Foreign Application: Domestic Application
Filing Date: 2001-11-26
Effective Receipt Date: 2003-04-30
Submission Type: BIO Sequence Filing
Filing Type:
Confirmation number: 7223
Attorney Docket Number: AREX-P03-002



Total Fees Authorized:


Digital Certificate Holder: cn=Matthew P. Vincent,ou=Registered Attorneys,ou=Patent and
Trademark Office,ou=Department of Commerce,o=U.S. Government,c=US
Certificate Message Digest: 42564af17858d01a5e989a7349db603e0614bd53



#15

TRANSMITTAL

Electronic Version v1.1
Stylesheet Version v1.1.0

Title of Invention	THERAPEUTIC BINDING AGENTS AGAINST MUC-1 ANTIGEN AND METHODS FOR THEIR USE											
<div>Application Number: 09/994466 </div> <div>Date: 2001-11-26</div> <div>First Named Applicant: Ragupathy Madiyaladan</div> <div>Confirmation Number: 7223</div> <div>Attorney Docket Number: AREX-P03-002</div>												
<p>I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.</p> <p>I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.</p> <table border="1"><thead><tr><th>Submitted by:</th><th>Elec. Sign.</th><th>Sign. Capacity</th></tr></thead><tbody><tr><td>Matthew P. Vincent Registered Number: 36,709</td><td>MPV</td><td>Attorney</td></tr></tbody></table>			Submitted by:	Elec. Sign.	Sign. Capacity	Matthew P. Vincent Registered Number: 36,709	MPV	Attorney				
Submitted by:	Elec. Sign.	Sign. Capacity										
Matthew P. Vincent Registered Number: 36,709	MPV	Attorney										
<table><tr><td>Documents being submitted</td><td>Files</td></tr><tr><td>us-bio-seq-trans</td><td>AREX-P03-002Sequence-usbios.xml</td></tr><tr><td></td><td>us-bio-seq-trans.dtd</td></tr><tr><td></td><td>us-bio-seq-trans.xsl</td></tr><tr><td>sequence-listing</td><td>AREX-P03-002SequenceListing.txt</td></tr></table>			Documents being submitted	Files	us-bio-seq-trans	AREX-P03-002Sequence-usbios.xml		us-bio-seq-trans.dtd		us-bio-seq-trans.xsl	sequence-listing	AREX-P03-002SequenceListing.txt
Documents being submitted	Files											
us-bio-seq-trans	AREX-P03-002Sequence-usbios.xml											
	us-bio-seq-trans.dtd											
	us-bio-seq-trans.xsl											
sequence-listing	AREX-P03-002SequenceListing.txt											
Comments												

AMINO ACID AND/OR NUCLEOTIDE SEQUENCE LISTING SUBMISSION

Electronic Version v13
Stylesheet Version v01

This is a request for filing the electronic Computer Readable Form copy of a sequence listing via the Electronic Filing System for a patent application under 37 CFR 1.821-1.825 instead of via one of the physical media specified in 37 CFR 1.824(c).

This communication has an attached file which is an electronic copy of the amino acid and/or nucleotide sequence listing for the previously mentioned United States patent application.

The electronic copy submitted herewith is the Computer Readable Form (CRF), as required by 1.821(e).

Any applicable fees associated with the filing of the electronic copy have been paid.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter). It may be in addition to an original CRF, filed to comply with the sequence rules.

This submission in electronic form comprises only the CRF of 37 CFR 1.821(e). I acknowledge that I am responsible for all additional requirements of amino acid and/or nucleotide sequence listing submissions as specified in 37 CFR 1.821 - 1.825.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter), and/or is in addition to an original CRF filed to comply with the sequence rules. If not made to comply with an originally filed CRF, it is identical to the sequences disclosed in the application as originally filed and/or the paper copy of the sequence listing as originally filed.

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office on the following date: 2003-04-30

Name: Matthew P. Vincent
Electronic Signature Mark: MPV

Attachment description:

CRF Biosequence

Compression software used: